Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Dec 14;32(12):E36–E41. doi: 10.1002/clc.20480

Clinical Implications of Defective B‐Type Natriuretic Peptide

Santosh G Menon 1,✉, Roger M Mills 1, Ute Schellenberger 1, Syed Saqhir 1, Andrew A Protter 1
PMCID: PMC6653732  PMID: 20014209

Abstract

Our understanding of the natriuretic peptide system continues to evolve rapidly. B‐type natriuretic peptide (BNP), originally thought to be a simple volume‐regulating hormone that is produced in response to cardiac stretch, has been shown to also play important roles in modulating bronchodilation, endothelial function, and cardiac remodeling. Recent data demonstrate that elevated levels of BNP in patients with heart failure do not represent a simple ratcheting up of normal production in response to increased stimulus. Instead, we now know that chronic stimulation of BNP synthesis induces a reversion to fetal gene expression, resulting in production of high molecular weight forms of BNP that are functionally deficient. Standard point‐of‐care BNP assays are immunoassays that will detect any molecule containing the target epitopes. Consequently, these assays cannot distinguish between defective, high molecular weight forms of BNP and normal, physiologically active BNP. In 2 separate evaluations, mass spectroscopy detected little, if any, normal BNP in patients with heart failure, despite the appearance of high circulating levels of immunoreactive BNP (iBNP) using commercial assays. Therefore, these commercial assays should be considered to be only an indication of myocardial stress. They do not measure physiologic BNP activity. This accounts for the “BNP paradox,” namely, that administration of exogenous recombinant human BNP (rhBNP, nesiritide) has substantial clinical and hemodynamic impact in the presence of high levels of circulating iBNP using commercial assays. In addition to its short‐term hemodynamic impact, rhBNP may have other important effects in this setting, and further investigation is warranted. Copyright © 2009 Wiley Periodicals, Inc.

Full Text

The Full Text of this article is available as a PDF (450.1 KB).

References

  • 1. McKie PM, Burnett JC Jr. B‐type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities. Mayo Clin Proc 2005; 80(8): 1029–1036. [DOI] [PubMed] [Google Scholar]
  • 2. Ramos H, de Bold AJ. Gene expression, processing, and secretion of natriuretic peptides: physiologic and diagnostic implications. Heart Fail Clin 2006; 2(3): 255–268. [DOI] [PubMed] [Google Scholar]
  • 3. Clerico A, Vittorini S. The cardiac natriuretic hormone system In: Clerico A, Emdin M, eds. Natriuretic Peptides: The Hormones of the Heart. 1st ed. Milan, Italy: Springer‐Verlag Italia; 2006; 21–64. [Google Scholar]
  • 4. Burnett JC Jr. Natriuretic peptides and remodeling in heart failure. Heart Fail Clin 2005; 1(1): 129–139. [DOI] [PubMed] [Google Scholar]
  • 5. Cataliotti A, Chen HH, Redfield MM, Burnett JC Jr. Natriuretic peptides as regulators of myocardial structure and function: pathophysiologic and therapeutic implications. Heart Fail Clin 2006; 2(3): 269–276. [DOI] [PubMed] [Google Scholar]
  • 6. Chen HH, Burnett JC Jr. Therapeutic potential for existing and novel forms of natriuretic peptides. Heart Fail Clin 2006; 2(3): 365–373. [DOI] [PubMed] [Google Scholar]
  • 7. Heublein DM, Huntley BK, Boerrigter G, et al. Immunoreactivity and guanosine 3′,5′‐cyclic monophosphate activating actions of various molecular forms of human B‐type natriuretic peptide. Hypertension 2007; 49(5): 1114–1119. [DOI] [PubMed] [Google Scholar]
  • 8. Liang F, O'Rear J, Schellenberger U, et al. Evidence for functional heterogeneity of circulating B‐type natriuretic peptide. J Am Coll Cardiol 2007; 49(10): 1071–1078. [DOI] [PubMed] [Google Scholar]
  • 9. Waldo SW, Beede J, Isakson S, Clopton P, Fitzgerald RL, Maisel AS. ProBNP represents “Altered forms” of BNP in acute decompensated congestive heart failure [Abst 100]. J Card Fail 2007; 13(6 suppl): S102–S103. [Google Scholar]
  • 10. Boerrigter G, Burnett JC Jr. Recent advances in natriuretic peptides in congestive heart failure. Expert Opin Investig Drugs 2004; 13(6): 643–652. [DOI] [PubMed] [Google Scholar]
  • 11. Liang F, Kapoun AM, Lam A, et al. B‐Type natriuretic peptide inhibited angiotensin II‐stimulated cholesterol biosynthesis, cholesterol transfer, and steroidogenesis in primary human adrenocortical cells. Endocrinology 2007; 148(8): 3722–3729. [DOI] [PubMed] [Google Scholar]
  • 12. Cataliotti A, Boerrigter G, Costello‐Boerrigter LC, et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide‐induced aldosterone activation in experimental heart failure. Circulation 2004; 109(13): 1680–1685. [DOI] [PubMed] [Google Scholar]
  • 13. Sica DA, Gottwald M, Li YP. Nesiritide appears to inhibit the rise in plasma aldosterone associated with furosemide diuresis. [Abstract 275]. J Cardiac Failure 2006. [Google Scholar]
  • 14. Kapoun AM, Liang F, O'Young G, et al. B‐type natriuretic peptide exerts broad functional opposition to transforming growth factor‐β in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 2004; 94(4): 453–461. [DOI] [PubMed] [Google Scholar]
  • 15. Tsuruda T, Boerrigter G, Huntley BK, et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 2002; 91(12): 1127–1134. [DOI] [PubMed] [Google Scholar]
  • 16. Hayashi M, Tsutamoto T, Wada A, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001; 37(7): 1820–1826. [DOI] [PubMed] [Google Scholar]
  • 17. Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J‐WIND): two randomised trials. Lancet 2007; 370(9597): 1483–1493. [DOI] [PubMed] [Google Scholar]
  • 18. Chen HH, Schirger JA, Wright RS, et al. Intravenous BNP at the time of acute anterior myocardial infarction in humans improves left ventricular remodeling [Abst 385]. Circulation 2005; 112(17 suppl): II–62. [Google Scholar]
  • 19. Hawkridge AM, Heublein DM, Bergen HR III, Cataliotti A, Burnett JC Jr, Muddiman DC. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP‐32) in severe human heart failure. Proc Natl Acad Sci USA 2005; 102(48): 17442–17447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Yandle TG, Richards AM, Gilbert A, Fisher S, Holmes S, Espiner EA. Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab 1993; 76(4): 832–838. [DOI] [PubMed] [Google Scholar]
  • 21. Bakris GL, Weir MR. Angiotensin‐converting enzyme inhibitor‐associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160(5): 685–693. [DOI] [PubMed] [Google Scholar]
  • 22. Epstein BJ. Elevations in serum creatinine concentration: concerning or reassuring? Pharmacotherapy 2004; 24(5): 697–702. [DOI] [PubMed] [Google Scholar]
  • 23. Sackner‐Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111(12): 1487–1491. [DOI] [PubMed] [Google Scholar]
  • 24. Yancy CW, Saltzberg MT, Berkowitz RL, et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am J Cardiol 2004; 94(5): 595–601. [DOI] [PubMed] [Google Scholar]
  • 25. Yancy CW, Massie BM, Krum H, Silver M, Stevenson LW, Mills RM. Chronic serial infusion of nesiritide is not associated with worsening renal function in chronic decompensated heart failure patients with renal insufficiency: An analysis from the FUSION‐II Trial [Abst 213]. J Card Fail 2007; 13(6 suppl): S136. [Google Scholar]
  • 26. Yancy CW, Singh A. Potential applications of outpatient nesiritide infusions in patients with advanced heart failure and concomitant renal insufficiency (from the Follow‐Up Serial Infusions of Nesiritide [FUSION I] trial). Am J Cardiol 2006; 98(2): 226–229. [DOI] [PubMed] [Google Scholar]
  • 27. Mentzer RM Jr, Oz MC, Sladen RN, et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA Trial. J Am Coll Cardiol 2007; 49(6): 716–726. [DOI] [PubMed] [Google Scholar]
  • 28.Heart Failure Society of America. HFSA 2006 comprehensive heart failure practice guideline. J Card Fail 2006; 12(1): e1–e126. [DOI] [PubMed] [Google Scholar]
  • 29. Mills RM, LeJemtel TH, Horton DP, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b‐type natriuretic peptide) in heart failure: a randomized, double‐blind, placebo‐controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol 1999; 34(1): 155–162. [DOI] [PubMed] [Google Scholar]
  • 30. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000; 343(4): 246–253. [DOI] [PubMed] [Google Scholar]
  • 31.Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002; 287(12): 1531–1540. [DOI] [PubMed] [Google Scholar]
  • 32. Shah MR, Hasselblad V, Stinnett SS, et al. Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure. Eur J Heart Fail 2002; 4(3): 297–304. [DOI] [PubMed] [Google Scholar]
  • 33. Gehlbach BK, Geppert E. The pulmonary manifestations of left heart failure. Chest 2004; 125(2): 669–682. [DOI] [PubMed] [Google Scholar]
  • 34. Akerman MJ, Yaegashi M, Khiangte Z, Murugan AT, Abe O, Marmur JD. Bronchodilator effect of infused B‐type natriuretic peptide in asthma. Chest 2006; 130(1): 66–72. [DOI] [PubMed] [Google Scholar]
  • 35. Jefferies JL, Denfield SW, Price JF, et al. A prospective evaluation of nesiritide in the treatment of pediatric heart failure. Pediatr Cardiol 2006; 27(4): 402–407. [DOI] [PubMed] [Google Scholar]
  • 36. Michaels AD, Klein A, Madden JA, Chatterjee K. Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake. Circulation 2003; 107(21): 2697–2701. [DOI] [PubMed] [Google Scholar]
  • 37. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult—summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2005; 112(12): 1825–1852. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES